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http://www.biomedcentral.com/1471-2342/13/35RESEARCH ARTICLE Open AccessThe use of high-frequency ultrasound imaging
and biofluorescence for in vivo evaluation of gene
therapy vectors
Nicola Ingram1*, Stuart A Macnab2, Gemma Marston1, Nigel Scott3, Ian M Carr1, Alexander F Markham1,
Adrian Whitehouse2 and P Louise Coletta1Abstract
Background: Non-invasive imaging of the biodistribution of novel therapeutics including gene therapy vectors in
animal models is essential.
Methods: This study assessed the utility of high-frequency ultrasound (HF-US) combined with biofluoresence
imaging (BFI) to determine the longitudinal impact of a Herpesvirus saimiri amplicon on human colorectal cancer
xenograft growth.
Results: HF-US imaging of xenografts resulted in an accurate and informative xenograft volume in a longitudinal
study. The volumes correlated better with final ex vivo volume than mechanical callipers (R2 = 0.7993, p = 0.0002 vs.
R2 = 0.7867, p = 0.0014). HF-US showed that the amplicon caused lobe formation. BFI demonstrated retention and
expression of the amplicon in the xenografts and quantitation of the fluorescence levels also correlated with
tumour volumes.
Conclusions: The use of multi-modal imaging provided useful and enhanced insights into the behaviour of gene
therapy vectors in vivo in real-time. These relatively inexpensive technologies are easy to incorporate into
pre-clinical studies.
Keywords: Biofluorescence, Ultrasound, Gene therapy, Imaging, Multi-modal, Colorectal cancerBackground
The use of non-invasive and accurate methods to deter-
mine tumour volume, as well as biodistribution and trans-
duction imaging of novel therapeutics, is essential in
experimental models in vivo. In particular, for gene ther-
apy studies, knowledge of maintenance, expression and
efficacy of the vector is a fundamental part of the testing
process [1]. However, this is rarely achieved during the
in vivo study of a novel gene therapy strategy, as often
only longitudinal calliper measurements of xenograft
growth or final histology after treatment are carried out.
The spread or loss of a vector is rarely detected during the
course of the experiment and for cancer treatment, not all
therapies will result in a reduction in tumour volume.* Correspondence: n.ingram@leeds.ac.uk
1School of Medicine, University of Leeds Brenner Building, St James’s
University Hospital, Leeds LS9 7TF, UK
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reproduction in any medium, provided the orTherefore it is important to be able to examine the impact
of a gene therapy vector during the in vivo testing phase
using different assessment criteria, whilst being mindful of
adhering to the principles of reduction, refinement and re-
placement in animal experiments.
Ultrasound is a non-invasive method that has been uti-
lised recently for tumour growth studies in vivo and is used
in the clinic for staging colorectal cancer among others
[2,3]. High-frequency ultrasound (HF-US) machines are
available for small animal imaging. They are relatively easy
to use and give high resolution greyscale images of mouse
anatomy [4]. They also give functional information on the
vascular structure of xenografts through the use of contrast
agents and are relatively inexpensive and portable com-
pared to MRI machines [5]. Mechanical callipers, however,
are still utilised extensively for therapeutic agent testing, es-
pecially in gene therapy applications on xenografts [6].
These are very cheap, non-invasive and allow multipleLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ever, mechanical callipers assume that the growth of xeno-
grafts is always ellipsoid and can only measure growth
above the skin surface of the animal. In addition, calliper
measurements are also affected by skin thickness, subcuta-
neous fat layer thickness and compressibility of the tumour
[7]. From our experience of xenograft growth in gene
therapy and other therapeutic studies, we know that this
ellipsoid growth pattern is rarely observed, especially as
the tumour volume becomes large (above approximately
300mm3).
A gene encoding a fluorescent or luminescent protein is
often incorporated into gene therapy vectors in order to
enumerate transduction efficiencies in vitro [8,9]. Moreover,
these markers are also very useful for in vivo studies.
Optical imaging chambers can be used to image the biodis-
tribution of a vector when administered and can give an
indication of the transduction efficiency in the target cells
[10]. Optical imaging systems also allow the maintenance
of a vector to be determined throughout the course of
treatment, as well as examining the genetic stability of the
vector over time. The first paper to prove that optical
imaging could be used to measure tumour growth used
bioluminescence of tumour cells in rat brain and was com-
pared to MRI scans for tumour volume [11]. Imaging of
stably-transfected cell lines containing red or green fluores-
cent protein (RFP or GFP) has been used to measure
tumour and metastatic growth [12,13]. Recent work has
also shown that fluorescent intensity correlates better with
tumour volume than fluorescent area [14].
In the study described herein, we aimed to determine
whether the use of HF-US measurements were more ac-
curate than mechanical callipers in assessing xenograft
volumes of tumour cells which were infected before in-
jection with an experimental gene therapy vector. The
use of HF-US to provide anatomical information on
tumour growth and BFI to monitor expression of a gene
therapy vector in longitudinal studies, were also analysed.
The vector we used was a Herpesvirus saimiri (HVS)
amplicon which contains the minimal elements for epi-
somal maintenance without infectious capabilities [9,15].
This gamma-2 Herpesvirus amplicon can incorporate
large amounts of heterologous DNA using a HVS-BAC
(bacterial artificial chromosome) system and infects a
broad range of human cells. The amplicon was previously
stably transfected into the SW480 colorectal cancer cell
line and contains a constitutively active GFP gene [16].
The presence of the GFP gene enabled monitoring of its
persistence during xenograft growth in this study.
Methods
Tumour model
The colorectal cancer cell line, HCT116 was stably-
transfected with an episomally-maintained Herpesvirussaimiri amplicon incorporating the GFP gene under the
control of the Cytomegalovirus (CMV) promoter. These
cells were grown in Dulbecco’s Modified Eagle Medium
(DMEM, Invitrogen) supplemented with 10% (v/v) foetal
calf serum, and 4ul/ml Hygromycin B (Sigma, Poole U.K.)
in 5% CO2 at 37
oC until there were enough cells for
xenograft set up (approximately 3-4 weeks from infec-
tion). Parental cell lines were grown in DMEM and serum
but no Hygromycin B. Two days before injection the
amplicon-transfected cells were transferred to medium
without any Hygromycin B.
1 × 106 each of the parental and amplicon-containing
cells were collected in 100ul of serum-free DMEM and
injected subcutaneously into the right flank of 8-10 week
old female CD1 nude mice to form xenografts. 6 mice
per group were used. All experiments were performed
following local ethical approval and in accordance with
the Home Office Animal Scientific Procedures Act 1986.
Tumour volume measurement with mechanical callipers
Tumours were measured with mechanical callipers three
times per week once the tumour became palpable
(approximately 7-10 days following injection). Tumour
volume was calculated as follows, unless otherwise
stated: [17]
Tumor volume ¼ 1=2ðgreatest longitudinal diameter
greatest transverse diameter2Þ
After 40 days a final calliper measurement was taken,
the xenografts were excised and weighed. If tumours
exceeded the maximum permitted size of 17mm diam-
eter, the mice were sacrificed earlier. Mechanical calliper
measurements were then taken in three dimensions
ex vivo and the following tumour volume was calculated,
unless otherwise stated:
Tumor volume ¼ length height π=6ð Þ
Anatomical imaging and tumour volume measurement
using HF-US
Once per week, mice were anaesthetised using 3% (v/v)
isofluorane and xenografts were imaged using a Vevo
770 high-frequency ultrasound machine (FUJIFILM
VisualSonics, Inc, Toronto, Canada) equipped with a 40
MHz transducer. The focal depth of the transducer was
placed at the mid-point of the centre of the tumour
whilst scanning. A 3D scan of the tumour was then per-
formed using the minimum step size possible for the
length of tumour and regions of interest were drawn
around the xenograft at approximately every 5 frames by
an operator with extensive experience of HF-US and
analysis [4]. A tumour volume was then calculated using
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struction of these xenografts.
Measurement of biofluorescence
Before sacrifice at day 40, xenografts were imaged in an
IVIS Spectrum (PerkinElmer, Inc, Massachusetts, USA).
Standard settings for GFP were used (excitation 500nm
and emission detected at 540nm) in epi-illumination at
high intensity. Binning was set at 8, field of view was
13.1cm and f stop was 2. Regions of interest of the same
size were drawn around each xenograft and the total ra-
diant efficiency ([photons/s]/[μW/cm2]) was calculated
within this using Living Image version 4.2 software
(PerkinElmer, Inc, Massachusetts, USA).
Histology and morphology of xenografts
Once the xenographs were excised, photographs were
taken of the intact tumours. The tumours were then cut
in half and fixed in 4% (w/v) paraformaldehyde in PBS
overnight. After processing and embedding in wax,
sections were dewaxed, rehydrated and stained with
haematoxylin and eosin. Sections were assessed by an ex-
perienced histopathologist.
Statistical analysis
Analysis of the tumour volumes and vector expression ob-
tained by these methods used Pearson correlations.
Positive correlations produced a positive R2 value and were
considered significant if p < 0.05. Agreement between the
methods was then further analysed by Bland-Altman plots
where the central line (mean of differences or bias) and 2
standard deviation (SD) limits of agreement were gener-
ated. The bias was considered significant if 0 was not in-
cluded within these standard deviation lines. These
calculations were carried out using GraphPad Prism ver-
sion 5 (GraphPad Software, Inc, La Jolla, California, USA).0 10 20 30
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Figure 1 Longitudinal growth of xenograft tumours using mechanica
using mechanical Vernier callipers on the external surface of the animal (in
ultrasound scans and calculating volumes by drawing regions of interest o
each group is shown (n = 5 for calliper measurements and 6 for HF-US) * d
tumour volumes (n = 2 from day 28).Results
Comparison of tumour growth curves generated using
mechanical callipers or HF-US
HF-US was used to determine the tumour volume during
the growth course of the xenografts derived from the par-
ental cell line and amplicon-infected cell line and com-
pared to the volume calculated from mechanical calliper
measurements. The tumour volumes generated from the
two methods are shown in Figure 1. The amplicon-
infected xenograft tumours grew more slowly than the par-
ental cells and this was detected by both measurement
methods. Tumour volumes by HF-US generated smaller
calculated tumour volumes than those using mechanical
callipers. At day 28 for example, calliper assessed xenograft
tumour volumes were calculated to be more than twice the
volumes generated using HF-US imaging. This difference
was even greater for the amplicon-infected xenografts as
these were 3.3 times larger when measured using mechan-
ical callipers compared to HF-US.
Comparison of tumour volume measurement methods to
the volume calculated using ex vivo calliper
measurements
HF-US measurements correlated more closely than
mechanical callipers (denoted as in vivo callipers on the
graphs) to the final ex vivo calliper measurement at the
end of the period of xenograft growth which is our most
accurate measurement (Figure 2 a and b). Thus the
tumour growth curves in Figure 1 are an over-estimation
if mechanical callipers are used compared to HF-US
measurements. Alternative formulae for tumour volume
calculation for both in vivo and ex vivo calliper measure-
ments were examined and compared to HF-US (Table 1)
[17]. As before, HF-US measurements correlated more
closely to either ex vivo volume formula than any in vivo
volume formula and no difference in correlation was40 50
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Figure 2 HF-US correlates more closely to the ex vivo tumour volume than using mechanical callipers in vivo. The tumour volume
generated by HF-US correlates more closely with the final ex vivo calliper volume than the in vivo calliper volume. (a) The Pearson correlation plot
of HF-US volumes versus ex vivo volumes has a higher R2 value (R2 = 0.7993, 95% CI = 0.6342-0.9724,p = 0.0002, two-tailed) than in vivo calliper
volumes versus ex vivo volumes (b) (R2 = 0.7867, 95% CI = 0.5421-0.9761, p = 0.0014, two-tailed). The solid line denotes line of best fit and dotted
lines indicate the 95% confidence band, n = 10.
Ingram et al. BMC Medical Imaging 2013, 13:35 Page 4 of 9
http://www.biomedcentral.com/1471-2342/13/35found between the two ex vivo volume formulae and HF-
US volumes. Using the formula π/6 × (L × W)3/2 for
in vivo calliper volumes gave a higher correlation to both
HF-US volumes and to mass of tumour than the other
two equations.
Comparison of tumour volume measurement methods to
final tumour mass
After sacrifice, the resulting xenograft tumours were
excised and weighed. Using Pearson correlation coefficients
and linear regression analysis, final in vivo calliper mea-
surements had a lower correlation coefficient to tumour
mass than HF-US. The tumour volumes calculated from
ex vivo calliper measurements of the excised xenograft had
the highest correlation coefficient to tumour mass (Figure 3Table 1 Pearson correlation coefficients of xenograft tumour
using mechanical callipers, HF-US or mass
π/6 × L × W × H
0.5 × L × W2 R2 0.7867
95% CI 0.5421-0.9761
p 0.0014
π/6 × L × W2 R2 0.7867
95% CI 0.5421-0.9761
p 0.0014
π/6 × (L × W)3/2 R2 0.8325
95% CI 0.6300-0.9817
p 0.0006
HF-US R2 0.7993
95% CI 0.6342-0.9724
p 0.0002
Mass (g) R2 0.9254
95% CI 0.7580-0.9946
p 0.0005
Three different formulae for generating in vivo tumour volumes using callipers are s
callipers on top. Each have been subject to pairwise comparison to determine the da, b and c and Table 1). Bland-Altman graphs show a
smaller 95% confidence interval between HF-US volumes
and the ex vivo calliper measurement compared to the
confidence interval between final in vivo calliper and the
ex vivo calliper measurements (Figure 4a and b). This dem-
onstrates a smaller difference between HF-US and the
ex vivo calliper measurement methods than between
in vivo and ex vivo callipers.
HF-US imaging and BFI of tumour anatomy and gene
therapy vector expression
In addition to HF-US, the use of BFI allowed the persist-
ence and expression of the amplicon to be tracked
in vivo. The HF-US images and photographs show that
the amplicon-containing xenografts grew in distinct lobesvolumes using different ellipsoid formulae and measured
0.5 × L × W × H HF-US Mass (g)
0.7867 0.8576 0.7843
0.5421-0.9761 0.7110-0.9827 0.4811-0.9792
0.0014 0.0001 0.0034
0.7867 0.8576 0.7843
0.5421-0.9761 0.7110-0.9827 0.4811-0.9792
0.0014 0.0001 0.0034
0.8325 0.8636 0.8492
0.6300-0.9817 0.7223-0.9835 0.6184-0.9860
0.0006 0.0001 0.0011
0.7993 0.8470
0.6342-0.9724 0.6135-0.9857
0.0002 0.0012
0.9254
0.7580-0.9946
0.0005
hown to the left and two different formulae for ex vivo tumour volumes using
ifferent correlation coefficients.
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Figure 3 Ex vivo callipers and HF-US correlated well to tumour mass. Final tumour mass correlated most strongly with ex vivo calliper
volume. Pearson correlations showed that in vivo calliper volumes correlated the least with tumour mass (Figure 3a, R2 = 0.7843,
95% CI = 0.4811-0.9792, p = 0.0034), followed by HF-US volume (Figure 3b, R2 = 0.8470, 95% CI = 0.6135-0.9857, p = 0.0012) whereas ex vivo calliper
volume showed the best correlation (Figure 3c, R2 = 0.9254, 95% CI = 0.7580-0.9946, p = 0.0005). Smaller tumours were not accurately weighed by
the balance therefore n = 8.
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were visible even from day 8 on the HF-US images in
comparison to the parental cell xenografts, thus allowing
very early detection of anatomic differences between the
two groups in vivo which was not possible to elucidate
from calliper measurements alone. The detailed greyscale
anatomical images using HF-US showed both lighter and
darker areas (derived from areas that are more or less(a) (
HF-US vs ex vivo callipers
Average
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0 200 400 600
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Figure 4 Bias assessment of each method for tumour volume calcula
compared to ex vivo calliper volumes. The ratios of HF-US to ex vivo callipe
measurements (x-axis). Bland-Altman plots were generated comparing the
volumes compared to ex vivo calliper volumes (b). The solid line denotes t
methods) and the dashed lines define the 95% confidence limits. The dott
than callipers therefore n = 11 in (a) and n = 10 in (b).echogenic to ultrasound) (Figure 5). The relatively lighter
areas within the xenograft were not adipose tissue and
corresponded to denser tumour tissue and from histology
we observed that the darker areas are necrotic tissue and
when the tumours were excised open, a liquid interior
core was found (Figure 6a). Amplicon infection of the
cells caused formation of syncitia (fused cells) during
xenograft growth, which was not evident in the parentalb)
in vivo callipers vs ex vivo callipers
Average
0 200 400 600 800
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4
R
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io
tion. HF-US volumes show less bias than in vivo calliper volumes when
r volumes (y-axis) were compared to the average value of the
bias between HF-US and ex vivo calliper volumes (a) and in vivo calliper
he bias (the average of the differences between the two measurement
ed line defines zero. HF-US could detect much smaller tumour volumes
Day 8
Day 14
Day 21
Day 28
Photograph 
at day 40
Parental Amplicon Outlined lobes
Day 40
Figure 5 High-frequency ultrasound imaging showing anatomical detail of xenograft growth that corresponds with ex vivo
examination. HF-US images of representative xenografts at the indicated day of growth. The first column shows images from an uninfected
xenograft (parental cell line). Note that by day 28 the imaging plane was changed to be able to fit the xenograft into the field of view and scan
over the whole tumour to generate the 3D image. The second column shows the amplicon infected xenograft. The third column outlines the
lobes visible in the amplicon xenograft. The photographs in the column are of each xenograft at day 40 showing the distinct lobes of the
amplicon infected xenograft compared to the uninfected xenograft.
Ingram et al. BMC Medical Imaging 2013, 13:35 Page 6 of 9
http://www.biomedcentral.com/1471-2342/13/35cell xenografts, as shown in Figure 6b. The presence of
lobes seen by HF-US can also be discerned in the fluores-
cent image taken by the IVIS Spectrum instrument
(Figure 6c).
Correlation of total radiant efficiency (fluorescence) and
tumour volume measurements
The measurement of levels of fluorescence was deter-
mined for the amplicon-infected xenografts using an IVIS
Spectrum and the Living Image software and plotted
alongside the ex vivo calliper volume (Figure 7a). These
measurements show a similar pattern for the amplicon
cell line in terms of fluorescence emission and calliper-
derived tumour volume. In vivo calliper measurements on
the final day of growth were less significantly correlated to
fluorescence measurements than calliper measurementsof the ex vivo xenografts (in vivo callipers, R2 = 0.8882,
95% CI = 0.3568-0.9963, p = 0.0164 compared with ex vivo
callipers, R2 = 0.9417 95% CI = 0.5518-0.9938, p = 0.0050)
(Figure 7b and c). HF-US volume measurements had a
better correlation coefficient to fluorescence measure-
ments than the ex vivo calliper measurements (R2 =
0.8895, 95% CI = 0.5606-0.9939, p = 0.0048) (Figure 7d).
However, it must be noted these are based on small num-
bers in each group, as only the amplicon-infected cells
contained GFP and not the parental cells.
Discussion
Multimodal imaging in gene therapy applications is a
useful tool to shed light on the behaviour of vectors dur-
ing in vivo testing. In this study, the use of HF-US im-
aging identified anatomical differences during growth
TT
V
V
N
(a) (b) (c)
Figure 6 Histological examination of the tumours. Haematoxylin and Eosin stained sections of xenografts. (a) Parental cell xenografts typically
showed islands of viable tumour (T) containing blood vessels (V) with large areas of necrosis (N). (b) amplicon infected xenografts show syncitia
(arrowed) present amongst the tumour cells, which were not observed in any of the parental cell line xenografts. (c) The IVIS Spectrum image
clearly shows the fluorescence emission from the xenograft lobes in an amplicon-infected xenograft, pseudo-coloured with the software default
settings of red to yellow for increasing intensity of signal (parental cell line xenografts contained no GFP and showed no signal by BFI).
Figure 7 Total radiant efficiency correlates with xenograft tumour volume. (a) The total radiant efficiency of each amplicon-infected
xenografts is plotted on the left y-axis of the graph alongside the ex vivo calliper tumour volume which is plotted on the right y-axis of the graph.
Total radiant efficiency compared to in vivo calliper volume is shown (b), R2 = 0.8882, 95% CI = 0.3568-0.9963, p = 0.0164 (n = 5 as one xenograft
was too small to be measured by callipers in vivo). Total radiant efficiency compared to ex vivo calliper volumes is shown in (c), R2 = 0.9417 95%
CI = 0.5518-0.9938, p = 0.0050, n = 6. Total radiant efficiency compared to HF-US volumes is shown in (d), R2 = 0.8895, 95% CI = 0.5606-0.9939,
p = 0.0048, n = 6.
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cell line in a xenograft model, even from day 8 after im-
plantation. It has been shown that HF-US can more ac-
curately measure tumour volume compared to the
traditional mechanical callipers, as demonstrated in this
paper and by others [2,18]. The use of different ellipsoid
volume formulae to generate the tumour volumes from
calliper measurements made small differences in accur-
acy where the highest correlation to mass was found
using π/6 × (L × W)3/2 rather than the more commonly
used 0.5 × L × W2 as described previously (although based
on only one paper [17]). Correlation to determining
volume by water displacement would be the gold standard
and would be a useful addition to this study. HF-US
volume generation and mechanical calliper measurements
by multiple operators would also be valuable for deter-
mining variability as these measurements are subject to
bias from operators. Jensen and colleagues compared
volumes determined by microCT, 18F-FDG-microPET
and external callipers, to an ex vivo reference volume
calculated by weight and density [19]. They demonstrated
that micro-CT was more accurate and reproducible
between observers than either external callipers or
18F-FDG-microPET. They also showed that 18F-FDG-
microPET was not so useful for determining tumour size,
although there was some correlation (R2 = 0.75). This
was similar to our findings with biofluorescence imaging.
As with our study, this functional tumour imaging
modality is useful for metabolic imaging and should give
an indication of the effect of a gene therapy vector on
tumour viability. In the current study, HF-US accurately
showed the slower tumour growth of the vector-
transfected cell line compared to the parental cell line, as
predicted from in vitro cell growth curves [16]. However,
lobe formation was unexpected. We are currently investi-
gating whether this is due to the GFP gene or other com-
ponents of the vector backbone. We also demonstrated
the utility of the different greyscale textures in monitoring
different patterns of growth. The discrimination of areas
of necrosis and high vascularity (using contrast agents)
was also possible. This should allow real-time monitoring
of agents that currently have little apparent effect on
tumour volume but may have useful effects of anti-
angiogenesis or inducing cell senescence. HF-US would be
of particular use for very small xenografts, orthotopic
models to in transgenic mice such as the Apc Min/+ mouse,
where callipers cannot access the tumour. Indeed, gene
therapy vectors are also used in non-cancer applications
such as diabetes or organ regeneration, where callipers
may not be used to measure disease progress or regres-
sion. In these cases, HF-US would be invaluable in moni-
toring progress longitudinally without sacrifice of mice.
In addition to HF-US images, the use of biofluorescence
allowed monitoring of tumour growth patterns and cor-related well with final tumour volumes (although it must
be noted this was based on small numbers with a wide
variation). This technique is a simple and very quick
method of visualising the tumour and much less expensive
than 18F-FDG-microPET, for example. Bio-fluorescence is
also applicable to patients. It is currently being trialled in
surgery on human tumours to define tumour margins for
resection [20]. The monitoring of these two cell lines
grown as xenografts showed that the presence and expres-
sion of the vector was maintained within the tumour over
the duration of the experiment. This information is of
great value for gene therapy applications as silencing of
the vector can occur, which may not be evident from
growth curves or even from immunohistochemistry on
ex vivo tumour sections for vector proteins. Linkage of the
therapeutic gene of interest to a fluorescent marker gene
via an IRES (internal ribosomal entry site) sequence or as
a fusion protein would yield valuable information on the
efficacy of expression during the time course of an in vivo
experiment. It may also be used to reduce costs by elimin-
ating animals in which the introduction of a vector by
injection has not been successful.
Conclusions
In conclusion we believe that multi-modal imaging pro-
vides useful and enhanced insights into the behaviour of
gene therapy vectors in vivo. Addition of imaging to
gene therapy protocols would be straightforward espe-
cially in the case of relatively inexpensive ultrasound
and biofluorescence imaging. The use of multi-modal
imaging can give important information on the behav-
iour of gene therapy vectors in real-time, rather than
traditional calliper measurements and final histological
examination.
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